CYBIN: FDA Clears Phase 2a Study for CYB004 in Anxiety Disorder
Ticker: HELP · Form: 6-K · Filed: Jan 23, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: drug-development, fda-clearance, clinical-trials, biotechnology
TL;DR
**Cybin just got FDA clearance for its CYB004 anxiety drug to enter Phase 2a trials, big news for its pipeline!**
AI Summary
Cybin Inc. announced on January 23, 2024, that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to begin a Phase 2a study for CYB004, a psychedelic treatment for Generalized Anxiety Disorder. This clearance follows positive Phase 1 safety data, showing rapid psychedelic effects at lower doses than native DMT, and a U.S. patent granted for CYB004 with protection through 2041. This is significant for investors because it moves CYB004 closer to market, potentially increasing Cybin's value if the Phase 2a study, expected to start in Q1 2024, yields positive results.
Why It Matters
FDA clearance for a Phase 2a study is a critical step in drug development, potentially validating CYB004's efficacy and expanding Cybin's market opportunity in mental healthcare.
Risk Assessment
Risk Level: medium — While FDA clearance is positive, the drug still needs to prove efficacy and safety in larger Phase 2a and subsequent trials, which carry inherent risks of failure.
Analyst Insight
A smart investor would monitor the progress of the CYB004 Phase 2a study closely, as positive results could significantly boost Cybin's valuation, but also be aware of the inherent risks in clinical trials.
Key Numbers
- 2041 — U.S. patent protection for CYB004 (indicates long-term intellectual property protection for the drug)
- Q1 2024 — expected start of Phase 2a study (timeline for the next stage of clinical trials)
Key Players & Entities
- Cybin Inc. (company) — the registrant announcing FDA clearance
- U.S. Food and Drug Administration (company) — the regulatory body that cleared the IND application
- Doug Drysdale (person) — Chief Executive Officer of Cybin Inc.
- CYB004 (drug) — investigational new drug for Generalized Anxiety Disorder
- Generalized Anxiety Disorder (condition) — the target indication for CYB004
- DMT (drug) — native compound compared to CYB004
Forward-Looking Statements
- CYB004 will successfully complete its Phase 2a study. (CYB004) — medium confidence, target: Q4 2024
- Cybin Inc.'s stock price will see increased volatility as Phase 2a results approach. (CYBN) — high confidence, target: Q4 2024
FAQ
What specific regulatory milestone did Cybin Inc. achieve for CYB004?
Cybin Inc. announced on January 23, 2024, that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 2a study of CYB004 in Generalized Anxiety Disorder.
What were the key findings from the Phase 1 study of CYB004?
The Phase 1 topline safety, pharmacokinetic (PK), and pharmacodynamic (PD) data for CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT.
When is Cybin Inc. planning to start the Phase 2a study for CYB004?
Cybin Inc. plans to initiate the randomized, double-blind, active controlled Phase 2a study for CYB004 in Q1 2024.
What is the significance of the U.S. composition of matter patent granted for CYB004?
The U.S. composition of matter patent granted for CYB004 provides intellectual property protection expected through 2041, which is crucial for the drug's long-term commercial potential.
Who signed the 6-K report on behalf of Cybin Inc. and when?
The 6-K report was signed by Doug Drysdale, Chief Executive Officer of Cybin Inc., on January 23, 2024.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-01-23 13:19:59
Filing Documents
- cybininc-form6xk01x23x2024.htm (6-K) — 11KB
- a1-23x2024cyb004indaccepta.htm (EX-99.1) — 22KB
- image_0.jpg (GRAPHIC) — 25KB
- 0001628280-24-001915.txt ( ) — 68KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date January 23, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated January 23, 2024